Literature DB >> 7878701

Blood distribution of mycophenolic acid.

L J Langman1, D F LeGatt, R W Yatscoff.   

Abstract

RS-61443 (RS) a morpholinoethyl ester of mycophenolic acid (MPA), can be considered a prodrug, as immunosuppressive activity is expressed only after hydrolysis to MPA upon absorption. Little is known about the blood distribution of MPA; such information would have an impact on the medium used for analysis of the drug in clinical trials. This was investigated by spiking whole blood having an initial temperature of either 4 degrees or 22 degrees C with increasing amounts of MPA ranging from 100 to 10,000 micrograms/L. These drug concentrations span the range seen when immunosuppressive doses of the RS are administered. This was followed by incubation of the blood at 37 degrees C for 0-120 min prior to separation of the cells. The drug concentration was measured in the plasma and whole blood fractions by high-performance liquid chromatography. MPA was almost exclusively found in the plasma fraction and did not exhibit any temperature or concentration dependence. The free or unbound fraction of MPA over the same concentration range was determined by ultracentrifugation and demonstrated a concentration dependence ranging from 7.2 to 16.5% of total drug for a concentration range spanning 500-10,000 micrograms/L. The drug was found to be primarily associated with the non-albumin proteins in the plasma. Less than 10% of the drug was found to be bound to lipoproteins. The data suggest that from an analytical standpoint, plasma, rather than whole blood, would be the most suitable medium for analysis because of the higher concentrations of the drug found in this fraction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7878701     DOI: 10.1097/00007691-199412000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.

Authors:  B Fulton; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

4.  Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study.

Authors:  Yoshiyuki Abe; Kurisu Tada; Ken Yamaji; Naoto Tamura
Journal:  Biomed Res Int       Date:  2021-01-23       Impact factor: 3.411

5.  Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease.

Authors:  Volkan Tahmaz; Martin H J Wiesen; Uta Gehlsen; Laura Sauerbier; Michael E Stern; Udo Holtick; Birgit Gathof; Christof Scheid; Carsten Müller; Philipp Steven
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-19       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.